AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05796635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herpecin L
Description: Participants in the Herpecin L arm will use the test product daily as a preventive product by applying the product twice daily. Also, participants will be told they can reapply the product if going outside into the cold, wind, or sun. If participants in the Herpecin L arm do experience a cold sore or fever blister, they will be instructed to use the product at the first sign of the cold sore and then at least four more times during the day until the cold sore is gone (they can use the product more often if they plan to go outside into the cold, sun, or wind).
Study NCT06372964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone administered orally, once daily.
Study NCT06372964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally, once daily.
Study NCT06353451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Detox
Description: In the intervention group, smartphone screen time will be reduced to less than 2 hours for 3 consecutive weeks.
Study NCT05571787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: 700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26
Study NCT05571787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26
Study NCT05195008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB113
Description: Administered as specified in the treatment arm.
Study NCT05195008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB113
Description: Administered as specified in the treatment arm.
Study NCT05195008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB113-Matching Placebo
Description: Administered as specified in the treatment arm.
Study NCT05195008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11^C]BIO-1819578
Description: Administered as specified in the treatment arm.
Study NCT06247709 — intervention group
Intervention type: OTHER
Intervention: Immunohistochemical expression in pitNET cells of KLHL14
Description: Lab essay evaluating the expression of KLHL 14
Study NCT05754840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPL-001
Description: High-CBD arm (MPL-001) a cannabidiol-enriched cannabis herbal extract which contains a 1:25 ratio of THC:CBD. The MPL-001 oil is produced by MediPharm Labs, each ml contains 50mg CBD and 2mg THC.
Study NCT05754840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPL-005
Description: Medium-CBD arm (MPL-005) a cannabidiol-enriched cannabis herbal extract which contains a 1:5 ratio of THC:CBD. The MPL-005 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 5mg THC.
Study NCT05754840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPL-009
Description: Balanced arm (MPL-009) a balanced 1:1 ratio of THC:CBD. The MPL-009 oil is produced by MediPharm Labs, each ml contains 25mg CBD and 25mg THC.
Study NCT06171438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Biomarkers
Description: Biomarkers of kidney damage in donors, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), beta2-microglobulin, alpha1-microglobulin, alpha2-macroglobulin and transferrin will be measured by ELISA.
Study NCT06171438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gene expression profiling of donor kidneys by microarray
Description: Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
Study NCT06171438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gene expression profiling of recipient kidneys by microarray
Description: Gene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
Study NCT06377826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercises
Description: group A will receive aerobic training like walking and cycling for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
Study NCT06377826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training
Description: this group will receive resistance training like gluteal bridge, calf raise, squats, seated shoulder press for 03 times per week approximately each exercise 5 to 10 minutes for 8 weeks.
Study NCT06377826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medication
Description: This group will be just on medication and no exercise will be given to this group
Study NCT05526833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: During the rTMS session, an electromagnetic coil is placed on the scalp of the subject's head. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in speech perception.
Study NCT06098235 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Diet advice
Description: The usual diet advice include recommendations in guidelines, such as reducing salt and fat intake.
Study NCT06770179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positional recruitment maneuver
Description: In the third group, in addition to the fixed PEEP, a recruitment maneuver will be performed at the end of the surgery before extubation. This will involve administering 6 breaths with VC × 2, I/E ratio of 1:1, and a plateau pressure of less than 35 cm H₂O, with 3 breaths in the right lateral decubitus position and 3 breaths in the left lateral decubitus position
Study NCT06773455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tralokinumab
Description: 600mg at week 0 followed by 300mg Q2W for 24 weeks
Study NCT06098235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ORIENT diet intervention
Description: The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
Study NCT06264895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: three times weekly exercise intervention with protein supplementation
Study NCT06378814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Caries Removal (No Pulp Exposure)
Description: Caries excavation technique where clinician leaves carious tissue so close to pulp
Study NCT06378814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Selective Caries Removal (No Pulp exposure)
Description: Complete caries removal even in areas so close to pulp
Study NCT06378814 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Pulpotomy (Pulp Exposed)
Description: In caes of Pulp exposure Amputation of inflamed coronal pulp and capping of remaining vital tissue
Study NCT04853784 — intervention group
Intervention type: PROCEDURE
Intervention: intracorporeal anastomosis
Description: intracorporeal anastomosis
Study NCT04962360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation standardized formula
Description: Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
Study NCT04962360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Low caloric formula (Powder added to water) without added vitamins and minerals
Study NCT05173454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education and Support
Description: The trained village health workers will provide breastfeeding education and support for male partners and mothers in intervention group for the six month period. During intervention trained village health workers will cover antenatal breastfeeding education to raise knowledge, awareness, support, and counseling on benefits of optimal breastfeeding practices and involvement in supporting breastfeeding mothers once at third trimester pregnancy period; Specific take-home print materials will be developed that support optimal breastfeeding practices and will be given for both partners during third trimester pregnancy; Telephone call counselling will be held to the male partners on optimal breastfeeding practices and involvement in supporting breastfeeding mothers at second week and third month postpartum and there will be three home visits during 6th week, 3.5 month and 5th month.
Study NCT06333509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT071
Description: a single CAR-T infusion of CT071
Study NCT05051774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1. Education
Description: Three monthly face-to-face group education with 8 to10 participants using a validated educational booklet will be provided by the researcher at the study hospital.
Study NCT05051774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2. Exercise
Description: The exercise intervention comprised of two elements as follows:~1. Three monthly hospital-based supervised group exercise consists of 8 to 10 participants. First two sessions: warm-up exercise-5 minutes, brisk walking-20 minutes at low intensity with music, and cool-down exercise-5 minutes. Third session: brisk walking for 30 minutes at moderate intensity with music.~2. Twelve-weeks home-based exercise: The participants will be asked to continue the exercise performed in the previous week at the hospital with music at least five times per week.
Study NCT05051774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3. Telephone follow-up
Description: A 20-minutes telephone follow-up at weeks 3, 7, and 11 for strengthening the volition of the participant to perform the exercise and follow the healthy diet at home.
Study NCT04780620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Intervention Group
Description: Parents will be involved in 8 weekly sessions.
Study NCT04749459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Moisturizer, Strawberry Flavor
Description: A single topical application of ChapStick Moisturizer, Strawberry Flavor will be applied to the appropriate 40 square centimeter (cm\^2) test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 milligram per centimeter square (mg/cm\^2), using 80 +/-2 milligrams (mg) of material.
Study NCT04749459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChapStick Moisturizer, Classic Flavor
Description: A single topical application of ChapStick Moisturizer, Classic Flavor will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
Study NCT04749459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ISO 24444:2010 P2 Standard Reference Sunscreen
Description: A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
Study NCT05152550 — intervention group
Intervention type: OTHER
Intervention: Non-severe pre-eclampsia
Description: Cases diagnosed as Non-severe pre-eclampsia after exclusion of severity features.
Study NCT05968573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Format with Captions
Description: A video with captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
Study NCT05968573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Format without Captions
Description: A video without captions created by the research team will be played to persuade patients to participate in HIV and Hepatitis C (HCV) screening.
Study NCT05968573 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Educator
Description: The video created by the research will be compared to a healthcare provider in terms of effectiveness in getting patients screened for HIV/HCV.
Study NCT05319639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.
Study NCT05319639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-Leucovorin
Description: Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.
Study NCT05319639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.
Study NCT05319639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered on day 1 of each cycle at 45mg/m2 at dose level 1; 67.5 mg/m2 at dose level 2 ; 90 mg/m2 at dose level 3; 112.5 mg/m2 at dose level 4 once every 14 days.
Study NCT05319639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 at dose level 1; 150 mg/m2 at dose level 2 once every 14 days.
Study NCT05319639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days.
Study NCT04833283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReOxy Cardio device, intermittent hypoxic-hyperoxic training ( IHHT)
Description: Perform 4 trainings daily of intermittent hypoxic hyperoxic trainings before surgery, using 40 min trainings periods, the patient will receive air with reduced oxygen content (12 %) through a mask under constant monitoring of heart rate (HR) and SpO2. As a safety measure, minimal SpO2 was set at 82 % and maximal accepted increase of heart rate was set to + 50 % of the initial HR. When these values would be reached, the supply of oxygen automatically switched to a hyperoxic gas mixture (35% - 40% O2), inhaling of which would be continued until SpO2 reached 100% (even if SpO2 would be lower before the procedure), which, depending on the rate of saturation reduction, will takes 1 to 3 min (mean 1 min and 50 s).
Study NCT04833283 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ReOxy Cardio device
Description: Perform 4 trainings daily of intermittent hypoxic-hyperoxic trainings before surgery, using 40 min trainings periods, whereas moistened air will be delivered through a mask under constant monitoring of heart rate (HR) and SpO2.
Study NCT05800249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0116
Description: This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
Study NCT05875675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Pioglitazone Oral Tablet
Description: Dietary Supplement: Pioglitazone 30 mg by mouth daily
Study NCT05875675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary: Supplement: Placebo
Study NCT05461950 — intervention group
Intervention type: PROCEDURE
Intervention: Extrauterine placental transfusion and physiology-based umbilical cord clamping
Description: Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room, the umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infants is breathing regularly (within 10 minutes after delivery)
Study NCT05461950 — intervention group
Intervention type: PROCEDURE
Intervention: Extrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping
Description: Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room and necessary respiratory support is initiated (CPAP or PPV) by a neonatal team. The umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infant is breathing regularly with or without support (at maximum 10 minutes after delivery)
Study NCT05461950 — intervention group
Intervention type: PROCEDURE
Intervention: Delayed umbilical cord clamping
Description: Umbilical cord is clamped and cut minimum 60 seconds after delivery to facilitate placental transfusion. Placenta is delivered after cord clamping. Infants needing respiratory support or other stabilisation are transferred to a warmer in the adjacent room where a neonatal team is waiting.
Study NCT06310980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartpen
Description: use of a smartpen connected with glucose sensor by an digital application
Study NCT05284760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T4 tablets.
Study NCT05284760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat T3 mini-tablets.
Study NCT05284760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat commercial tablets.
Study NCT04992520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 53G
Description: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast
Study NCT04992520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a 2457T
Description: Shigella flexneri strain 2457T (Lot 1617) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.
Study NCT05828693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SysLife©
Description: Use of the SysLife© application, with 2-, 4-, 6- and 8-month follow-up.
Study NCT05828693 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SysLife©, as intervention after closing the RCT-design
Description: Use of the SysLife© application after 4-month waiting period, with 2- and 4-month follow-up.
Study NCT04732741 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Gamma-synuclein
Description: Gamma-synuclein salivary levels measured using ELISA assay
Study NCT04732741 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Incisional biopsy
Description: A) Biopsy (reference standard): biopsy for group 1 will be performed by specialists in the national cancer institute.~B) Biopsy for oral potentially malignant lesions will be performed by the candidate from the most representative region.
Study NCT04732741 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional visual and tactile examination
Description: Conventional visual and tactile examination using light and mirror
Study NCT05997641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF-003
Description: Oral administration by capsules (1 mg, 5 mg, or 25 mg).
Study NCT05997641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually matching 0 mg DF-003 capsules.
Study NCT05409261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Recombinant vaccine, contains Adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein
Study NCT06493955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity for 12 months
Description: 6 additional months of adapted physical activity after the 6 first months
Study NCT06493955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted physical activity for 6 months
Description: standard 6-month prescription for adapted physical activity
Study NCT04925609 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Brigatinib
Description: Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
Study NCT05095207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
Study NCT05095207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150 mg orally daily, day 1 to 28.
Study NCT06542055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative pulmonary rehabilitation exercise
Description: Besides receiving preoperative thoracic surgery health education manuals and postoperative regular pulmonary rehabilitation exercises, they also receive exercises originally tailored for pulmonary rehabilitation, including upper-body resistance exercise, lower-body resistance exercise, aerobic exercise, and respiratory muscle training for 4-7 days before surgery. In addition, a communication app group will be set up and an exercise diary will be provided.
Study NCT06542055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative education and postoperative exercise
Description: Receiving preoperative thoracic surgery health education manual and postoperative regular pulmonary rehabilitation exercises